Skip to main content

Peer Review reports

From: Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Original Submission
17 Feb 2022 Submitted Original manuscript
18 Mar 2022 Reviewed Reviewer Report - Kirsty Loudon
29 Mar 2022 Author responded Author comments - Nicholas A Turner
Resubmission - Version 2
29 Mar 2022 Submitted Manuscript version 2
Publishing
28 Apr 2022 Editorially accepted
16 May 2022 Article published 10.1186/s13063-022-06370-1

You can find further information about peer review here.

Back to article page